Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?

Imatinib has been associated with a decline in GFR. It is not certain (and probably doubtful) that this represents kidney damage. If no other causes can be identified, a change could be appropriate. Bosutinib has been associated with a similar decline so nilotinib or dasatinib might be better option...

I would definitely consider changing the TKI in a CP-CML patient who develops renal insufficiency for which no other cause has been identified, especially if the patient has a relatively recent diagnosis of CML (within a year) and is not achieving his/her hematologic or molecular milestones. I would...